I, along with Delta Air Lines Assistant General Counsel Stephanie Bignon, recently authored an article for Corporate Compliance Insights addressing the latest developments impacting SEC periodic reporting disclosure practices.

“Public companies have been monitoring and rapidly adapting to a wide array of developments impacting periodic reporting disclosure practices over the last year,” we wrote in the article.

In addition to various SEC rules changes that have been adopted over the last year, we provided an extensive overview of four key areas which are anticipated to impact periodic reporting for the remainder of 2021:

  1. Continuing Evolution of COVID-19

Public companies have been including a dedicated COVID-19 discussion as a lead-in section to their MD&A, which is likely to continue – although the lengths of these sections might be reduced as the pandemic wanes.

  1. ESG-Related Disclosures in Focus

Following the change in presidential administration, ESG-related disclosures will be an area of significantly increased focus by the SEC.

  1. Key Performance Indicators

Early 2020 guidance from the SEC reminded companies about the need to disclose key variables and factors that management uses to manage its business.

  1. Non-GAAP Financial Measures

Non-GAAP compliance remains a significant ongoing area of focus from the SEC.

For a more in-depth look at these four key areas, read the full article, “Periodic Reporting for Public Companies in 2021: What Lies Ahead,” that was published by Corporate Compliance Insights on April 14 and is available online.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Kevin Douglas Kevin Douglas

Kevin Douglas has deep experience representing public companies on corporate and securities laws related matters, including companies within the healthcare industry. Kevin’s public company practice focuses on corporate governance matters, securities laws compliance, mergers and acquisitions, corporate finance and shareholder activism. His representative…

Kevin Douglas has deep experience representing public companies on corporate and securities laws related matters, including companies within the healthcare industry. Kevin’s public company practice focuses on corporate governance matters, securities laws compliance, mergers and acquisitions, corporate finance and shareholder activism. His representative experience has ranged from providing SEC disclosure advice to the audit committee of a Fortune 100 company to representing an NYSE-listed company in connection with its $4.3 billion acquisition by another public company to representing another NYSE-listed company in connection with its issuance of $2.2 billion in senior notes. Kevin has also represented private companies in a wide variety of mergers and acquisition, corporate finance, and other corporate law matters.